| Shin, Eun-Seok |
PROTECT-HBR, NCT04416581: Potassium-Competitive Acid Blocker Versus pROton-Pump Inhibitor for GastroproTECTion Strategies In Patients at High Gastro-Intestinal Bleeding Risk Receiving Antithrombotic Therapy |
|
|
| Recruiting | 4 | 3100 | RoW | PPI, P-CAB 50 | Duk-Woo Park, MD | Coronary Artery Disease, Percutaneous Coronary Intervention, Acute Coronary Syndrome, Myocardial Infarction | 09/26 | 12/27 | | |
NCT05758896: Study of APX-115 in Contrast Induced Acute Kidney Injury in Subjects Undergoing PCI |
|
|
| Recruiting | 2 | 280 | US, RoW | Isuzinaxib (APX-115), Isuzinaxib Hydrochloride, Placebo | Aptabio Therapeutics, Inc. | Contrast Induced Acute Kidney Injury | 09/24 | 12/24 | | |
NCT05648838: Evaluation of Safety and Efficacy of Pivot Balloon to Monitoring Acute RV Failure and Reduction of FTR |
|
|
| Completed | N/A | 7 | RoW | Pivot Balloon Catheter | Tau Pnu Medical Co., Ltd. | Functional Tricuspid Regurgitation | 01/23 | 01/23 | | |
| Recruiting | N/A | 7 | RoW | TIRA catheter, CA10 and ohter 3 models | Tau Pnu Medical Co., Ltd. | Hypertrophic Obstructive Cardiomyopathy | 04/26 | 08/26 | | |
NCT05096442: Compare the Safety and Efficacy of Genoss® DCB and SeQuent® Please NEO in Korean Patients With Coronary De Novo Lesions |
|
|
| Completed | N/A | 204 | RoW | GENOSS® DCB, Paclitaxel Coated PTCA Balloon catheter, SeQuent® Please NEO | Genoss Co., Ltd. | Coronary Artery Disease | 06/23 | 11/23 | | |
| Recruiting | N/A | 140 | RoW | Renal Denervation | Kalos Medical | Hypertension, Vascular Diseases, Cardiovascular Diseases | 07/23 | 04/24 | | |
NCT05854095: The Study for Evaluation of Acute Phase Safety and Efficacy of 'Pivot Bridge' to Short-term Treat FTR |
|
|
| Completed | N/A | 15 | RoW | Pivot Bridge | Tau Pnu Medical Co., Ltd. | Functional Tricuspid Regurgitation | 10/23 | 12/23 | | |
FLASH, NCT05388357: AI Quantitative Coronary Angiography Versus Optical Coherent Tomography Guidance for Coronary Stent Implantation |
|
|
| Completed | N/A | 400 | RoW | Intervention Procedure: PCI | Asan Medical Center, Korea Medical Device Development Fund, Medipixel,Inc | Coronary Vessels, Procedure PCI | 06/24 | 10/24 | | |
| Recruiting | N/A | 1500 | RoW | Balloon angioplasty | Seung-Jung Park, CardioVascular Research Foundation, Korea, B. Braun Korea Co., Ltd. | Coronary Artery Disease, Angioplasty, Balloon | 12/24 | 06/28 | | |
| Recruiting | N/A | 20000 | RoW | | Seung-Jung Park, CardioVascular Research Foundation, Korea, Abbott Medical Devices | Coronary Artery Disease | 04/37 | 04/37 | | |
REVERSE, NCT05846893: Drug-Coated Balloon vs. Drug-Eluting Stent for Clinical Outcomes in Patients With Large Coronary Artery Disease |
|
|
| Recruiting | N/A | 1436 | RoW | SeQuent® Please NEO drug-coated balloon catheter, Current-generation drug-eluting stent | B. Braun Medical Industries Sdn. Bhd., B. Braun Melsungen AG, Ulsan University Hospital, European Cardiovascular Research Center, Seoul National University Hospital, Universität des Saarlandes | Coronary Artery Disease, Myocardial Ischemia, Acute Coronary Syndrome, Coronary Stenosis, De Novo Stenosis | 10/26 | 09/28 | | |
NCT04619277: Impact of Drug-coated Balloon Treatment in de Novo Coronary Lesion |
|
|
| Recruiting | N/A | 10000 | RoW | drug-coated balloon | Ulsan Medical Center | Drug-coated Balloon | 12/30 | 12/30 | | |
| Doh, Joon-Hyung |
| Recruiting | N/A | 20000 | RoW | | Seung-Jung Park, CardioVascular Research Foundation, Korea, Abbott Medical Devices | Coronary Artery Disease | 04/37 | 04/37 | | |
REVERSE, NCT05846893: Drug-Coated Balloon vs. Drug-Eluting Stent for Clinical Outcomes in Patients With Large Coronary Artery Disease |
|
|
| Recruiting | N/A | 1436 | RoW | SeQuent® Please NEO drug-coated balloon catheter, Current-generation drug-eluting stent | B. Braun Medical Industries Sdn. Bhd., B. Braun Melsungen AG, Ulsan University Hospital, European Cardiovascular Research Center, Seoul National University Hospital, Universität des Saarlandes | Coronary Artery Disease, Myocardial Ischemia, Acute Coronary Syndrome, Coronary Stenosis, De Novo Stenosis | 10/26 | 09/28 | | |
| Jo, Jae-Cheol |
| Recruiting | 3 | 357 | Europe, Japan, US, RoW | Belantamab mafodotin, Pomalidomide, Dexamethasone, Bortezomib | GlaxoSmithKline | Multiple Myeloma | 01/24 | 05/29 | | |
|
|
|
|
|
|
|
|
|
|
|
|
|
DREAMM-10, NCT06679101: A Study of Belantamab Mafodotin Administered in Combination With Lenalidomide and Dexamethasone (BRd) Versus Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Participants With Newly Diagnosed Multiple Myeloma (NDMM) Who Are Ineligible for Autologous Stem Cell Transplantation (TI-NDMM) |
|
|
| Recruiting | 3 | 520 | RoW | Belantamab mafodotin, Lenalidomide, Dexamethasone, Daratumumab | GlaxoSmithKline | Multiple Myeloma, Newly Diagnosed Multiple Myeloma | 12/30 | 04/32 | | |
CRESCENDO, NCT06072131: To Evaluate Efficacy of Belinostat or Pralatrexate in Combination Against CHOP Alone in PTCL |
|
|
| Recruiting | 3 | 504 | Europe, US, RoW | Belinostat Injection, Beleodaq®, Pralatrexate Injection, Folotyn®, CHOP, Cyclophosphamide, Hydroxydaunorubicin (doxorubicin), Oncovin (vincristine), and Prednisone, COP, Cyclophosphamide, Oncovin (vincristine), and Prednisone | Acrotech Biopharma Inc. | Peripheral T Cell Lymphoma | 07/30 | 11/30 | | |
DISTINKT, NCT04414163: A Study of IMC-001 in Subjects With Relapsed or Refractory Extranodal NK/T Cell Lymphoma, Nasal Type |
|
|
| Active, not recruiting | 2 | 23 | RoW | IMC-001, Not confirm yet | ImmuneOncia Therapeutics Inc. | Extranodal NK/T-cell Lymphoma, Nasal Type, Extranodal NK/T-cell Lymphoma | 07/24 | 02/26 | | |
DREAMM 5, NCT04126200 / 2019-001138-32: Platform Study of Belantamab Mafodotin as Monotherapy and in Combination With Anti-cancer Treatments in Participants With Relapsed/Refractory Multiple Myeloma (RRMM) |
|
|
| Active, not recruiting | 2 | 209 | Europe, Canada, US, RoW | Belantamab mafodotin, GSK3174998, Feladilimab, Nirogacestat, Dostarlimab, Isatuximab, Lenalidomide, Dexamethasone, Pomalidomide | GlaxoSmithKline | Multiple Myeloma | 02/29 | 02/29 | | |
|
|
|
|
